Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | KEYNOTE-866: pembrolizumab + chemotherapy for bladder cancer

Arlene Siefker-Radtke • 15 Feb 2020
GU Cancers 2020
Bladder Cancer Genitourinary Cancer Antibodies Checkpoint Inhibitors Pembrolizumab
KEYNOTE-866

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the KEYNOTE-866 trial (NCT03924856), which investigated perioperative pembrolizumab plus neoadjuvant chemotherapy versus perioperative placebo plus neoadjuvant chemotherapy for cisplatin-eligible muscle-invasive bladder cancer. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Arlene Siefker-Radtke

1:47
The future role of erdafitinib in advanced urothelial carcinoma
Arlene Siefker-Radtke • 4 Jun 2023
1:34
RAGNAR: histology-agnostic trial of erdafitinib in FGFR3-mutant tumors
Arlene Siefker-Radtke • 4 Jun 2023
2:34
NORSE: erdafitinib and cetrelimab in urothelial carcinoma
Arlene Siefker-Radtke • 4 Jun 2023
1:15
What role will erdafitinib play in treating metastatic urothelial carcinoma?
Arlene Siefker-Radtke • 4 Jun 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals